Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.

Abstract: The invention provides combination therapies that include CV-8972 and CV-8814. The combination therapies improve cardiac efficiency and thus are useful for treating cardiovascular conditions in a subject. The invention also provides methods of treating conditions using both CV-8972 and CV-8814 and pharmaceutical compositions that contain both CV-8972 and CV-8814.

Abstract: The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.

Abstract: The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism.

Abstract: The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.

Abstract: The invention provides methods of treatment of heart failure with preserved ejection fraction (HFpEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of heart failure with hibernating myocardium using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: Methods and systems describe providing for aggregated media content selection and broadcasting. The system receives service providers associated with a user, and also receives media content and associated content metadata. The system then configures a user interface on a client device for navigation and selection of media content. The system determines available broadcasting devices, and receives a media content selection and broadcasting device selection. The system then initiates playback of the media content on the selected broadcasting device.

Abstract: Methods and compositions comprising a biomaterial that are useful for treating a subject with a condition are described. More specifically, methods of treating a subject with a cardiovascular condition comprising delivering a biomaterial comprising extracellular matrix, and delivering a therapeutic cardiac device or therapeutic agents to the subject are described. In addition, methods of delivering extracellular matrix to a subject are also described.

Abstract: Methods and compositions comprising a biomaterial that are useful for treating a subject with a condition are described. More specifically, methods of treating a subject with a cardiovascular condition comprising delivering a biomaterial comprising extracellular matrix, and delivering a therapeutic cardiac device or therapeutic agents to the subject are described. In addition, methods of delivering extracellular matrix to a subject are also described.